Origin and Dissemination across the Colombian Andes Mountain Range of Sulfadoxine-Pyrimethamine Resistance in
            <i>Plasmodium falciparum</i>

Corredor, Vladimir; Murillo, Claribel; Echeverry, Diego F.; Benavides, Julie; Pearce, R. P.; Roper, Cally; Guerra, Ángela Patricia; Osorio, Lyda

doi:10.1128/aac.00036-10

Cited by 23 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CQ-resistant parasites in Southeast Asia near the Thai–Cambodian border are thought to have seeded the introduction of CQ-resistant parasites into Africa, carried by individuals with the infection 159 . Resistance to pyrimethamine also emerged in Southeast Asia as well as in South America, and with triple-mutant dhfr Asian alleles, spread to Africa (red arrows) 160,161 . Pyrimethamine-resistant dhfr alleles also emerged independently in Africa 162,163 .…”

Section: Figurementioning

confidence: 99%

Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic

Blasco

Leroy

Fidock

2017

Nat Med

428

419

View full text Add to dashboard Cite

The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.

show abstract

Section: Figurementioning

confidence: 99%

Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic

Blasco

Leroy

Fidock

2017

Nat Med

428

419

View full text Add to dashboard Cite

show abstract

“…Importantly, even highly endemic countries such as Venezuela, Colombia, Peru, and Panama significantly reduced malaria transmission. However, parasite resistance to several anti-malarial drugs (Corredor et al, 2010; Feachem et al, 2009; WHO, 2005), mosquito resistance to DDT and other insecticides, economical constraints, and unclear malaria control policies significantly limited the progress of this early program (Roberts and Andre, 1994; WHO, 1998). …”

Section: Malaria Control In Non-amazonian Regions Of Latin Americamentioning

confidence: 99%

Prospects for malaria elimination in non-Amazonian regions of Latin America

Herrera¹,

Quiñónes²,

Quintero³

et al. 2012

Acta Tropica

Self Cite

View full text Add to dashboard Cite

Latin America contributes 1 to 1.2 million clinical malaria cases to the global malaria burden of about 300 million per year. In 21 malaria endemic countries, the population at risk in this region represents less than 10% of the total population exposed worldwide. Factors such as rapid deforestation, inadequate agricultural practices, climate change, political instability, and both increasing parasite drug resistance and vector resistance to insecticides contribute to malaria transmission. Recently, several malaria endemic countries have experienced a significant reduction in numbers of malaria cases. This is most likely due to actions taken by National Malaria Control Programs (NMCP) with the support from international funding agencies. We describe here the research strategies and activities to be undertaken by the Centro Latino Americano de Investigación en Malaria (CLAIM), a new research center established for the non-Amazonian region of Latin America by the National Institute of Allergy and Infectious Diseases (NIAID). Throughout a network of countries in the region, initially including Colombia, Guatemala, Panama, and Peru, CLAIM will address major gaps in our understanding of changing malaria epidemiology, vector biology and control, and clinical malaria mainly due to Plasmodium vivax. In close partnership with NMCPs, CLAIM seeks to conduct research on how and why malaria is decreasing in many countries of the region as a basis for developing and implementing new strategies that will accelerate malaria elimination.

show abstract

“…This has resulted in the isolation of parasite populations and limited dispersion of mutations, such as those associated with anti-malarial drug resistance in P. falciparum populations, which may have consequences for malaria control strategies. Drug resistance associated mutations that are common in the Amazon and Orinoco Basins have not been introduced to the Pacific coast region (Bacon et al 2009, Corredor et al 2010). Additionally, there is a dense forest, known as the Darien gap, which geographically separates Central America from South America and maintains parasite populations that harbour significantly different drug sensitivity profiles (Restrepo-Pineda et al 2008).…”

Section: Epidemiology Of Malaria-related Anaemia In Lamentioning

confidence: 99%

Malaria-related anaemia: a Latin American perspective

Quintero

Siqueira

Tobón

et al. 2011

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Malaria is the most important parasitic disease worldwide, responsible for an estimated 225 million clinical cases each year. It mainly affects children, pregnant women and non-immune adults who frequently die victims of cerebral manifestations and anaemia. Although the contribution of the American continent to the global malaria burden is only around 1.2 million clinical cases annually, there are 170 million inhabitants living at risk of malaria transmission in this region. On the African continent, where Plasmodium falciparum is the most prevalent human malaria parasite, anaemia is responsible for about half of the malaria-related deaths. Conversely, in Latin America (LA), malaria-related anaemia appears to be uncommon, though there is a limited knowledge about its real prevalence. This may be partially explained by several factors, including that the overall malaria burden in LA is significantly lower than that of Africa, that Plasmodium vivax, the predominant Plasmodium species in the region, appears to display a different clinical spectrus and most likely because better health services in LA prevent the development of severe malaria cases. With the aim of contributing to the understanding of the real importance of malaria-related anaemia in LA, we discuss here a revision of the available literature on the subject and the usefulness of experimental animal models, including New World monkeys, particularly for the study of the mechanisms involved in the pathogenesis of malaria.

show abstract

Origin and Dissemination across the Colombian Andes Mountain Range of Sulfadoxine-Pyrimethamine Resistance in Plasmodium falciparum

Abstract: The therapeutic efficacy of sulfadoxine-pyrimethamine (SP) in treating uncomplicated

Cited by 23 publications

References 27 publications

Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic

Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic

Prospects for malaria elimination in non-Amazonian regions of Latin America

Malaria-related anaemia: a Latin American perspective

Contact Info

Product

Resources

About